James George to Antibodies, Monoclonal
This is a "connection" page, showing publications James George has written about Antibodies, Monoclonal.
Connection Strength
0.646
-
Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher. 2006 Apr; 21(1):49-56.
Score: 0.230
-
Thrombotic thrombocytopenic purpura: from the bench to the bedside, but not yet to the community. Ann Intern Med. 2003 Jan 21; 138(2):152-3.
Score: 0.184
-
Thrombotic thrombocytopenic purpura: 2008 update. Cleve Clin J Med. 2008 May; 75(5):369-75.
Score: 0.066
-
Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost. 2006 Aug; 4(8):1664-72.
Score: 0.059
-
Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura. Int J Hematol. 2005 Feb; 81(2):119-25.
Score: 0.053
-
Inhibition of the acute-phase response in vivo by anti-gp130 monoclonal antibodies. Br J Haematol. 1996 Dec; 95(3):443-51.
Score: 0.030
-
Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev. 2013 Jul; 27(3):137-45.
Score: 0.024